ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes

Salem, NH, August 17, 2016 --(PR.com)-- ALPCO recently released new and improved, highly specific Total Adiponectin and HMW & Total Adiponectin ELISAs. The new generation of these colorimetric assays provides researchers with the confidence to measure adiponectin for the study of high molecular weight (HMW) to total ratios in type 2 diabetes (T2D), metabolic syndrome, obesity, coronary artery disease (CAD), and non-alcoholic fatty liver disease (NAFLD). As compared to the previous generation of the kits, the new ELISAs can be run in three hours or less with fewer incubation steps and also offer cost savings to users.

“Studying the ratio of HMW to total adiponectin has become instrumental in better understanding insulin resistance,” explains ALPCO’s President, Sean Conley. “We developed the new Total Adiponectin and HMW & Total Adiponectin ELISAs not only to help save labs time and money, but also to make sure users have access to reliable options when conducting such important work within the diabetes research field.”

ALPCO’s Total Adiponectin and HMW & Total Adiponectin ELISAs are For Research Use Only in the United States. To ensure a smooth transition for users to the new assays, serum samples were run on each version of the kits. Correlation data suggested that the new assays perform equivalently to the older versions. Visit alpco.com to learn more about the new Total Adiponectin ELISA and HMW & Total Adiponectin ELISA.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. In 2008, ALPCO expanded its capabilities with the launch of an organically developed product line focused in the area of diabetes and obesity research while also remaining true to its roots by continuing to provide “Immunoassays Beyond the Ordinary.”